thought call
pfizer result larg unev compani benefit notabl
follow merck neg revis guidanc earlier morn inde
didnt see hear much thesis-chang acknowledg result
better expect guidanc reiter despit absorb number
fx headwind howev key product perform larg mix
major stand-out eliqui benefit pull-forward realiz
vyndaqel price continu move wrong direct still wait
improv visibl tangibl action around compani effort address loe
cliff stock benefit extent past week
program antivir vaccin program optimist messag
point would argu need see clinic data ignor commerci
aspect treatment moment there number competitor
dataset expect emerg interim could upset calculu net-net
still wait pipelin matur diff data ibranc palla data
earli step-up busi develop activ see share re-set
meaning higher rais pt reflect today updat remain equal weight
vyndaqel dynam vyndaqel expect most-impact product
pfizer top-lin growth absolut term growth
come us though expect consensu estim may come
appreci commentari today detail declin new patient start in-lin
recent kol discuss link note realiz price per treat
vyndaqel patient fell vs
stall new start extent difficult overcom balanc
forecast /ww rev
miss ou expect drag remaind
adjust estim adjust estim reflect expect
impact revs/opex temper vyndaqel launch expect net impact
bring ep estim
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
idc link barclay live interact chart
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight pfizer remainco expect
emerg improv growth profil limit
near-term loe overhang though larg
appreci reflect share remainco
alreadi premium peer expans
uncertain hing meaning
success adjuv breast cancer ibranc would
solid win share would clear path
toward addit margin expans coupl
pipelin win diff
strateg busi develop address
neg ibranc adjuv data failur realiz cost
save upjohn spin-off poor busi
chang model
adjust estim reflect expect impact revs/opex
temper vyndaqel launch expect net impact bring ep
estim
takeaway kol call attr-cm impact sensit analysi
mn except per share datanewpriornewpriornewpriortot gross total ebit oper interest ebt pre-tax net incom common ep non-gaap share outstand barclay
carter gould herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
unless otherwis indic price sourc bloomberg reflect close price relev trade market may
last avail price time public
